Core Points - Ashford Hospitality Trust, Inc. announced multiple dividends for its preferred stock series for the fourth quarter ending December 31, 2025, with payments scheduled for January 15, 2026 [1][2][3][4][5][6][7][8][9][10][11][12][13] Dividend Announcements - A dividend of $0.5281 per diluted share was declared for the 8.45% Series D Cumulative Preferred Stock [1] - A dividend of $0.4609 per diluted share was declared for the 7.375% Series F Cumulative Preferred Stock [2] - A dividend of $0.4609 per diluted share was declared for the 7.375% Series G Cumulative Preferred Stock [3] - A dividend of $0.46875 per diluted share was declared for the 7.50% Series H Cumulative Preferred Stock [4] - A dividend of $0.46875 per diluted share was declared for the 7.50% Series I Cumulative Preferred Stock [5] - Monthly cash dividends of $0.16667 per share for Series J Redeemable Preferred Stock were announced for three payment dates [6] - Monthly cash dividends of $0.17708 per share for Series K Redeemable Preferred Stock were announced for one specific CUSIP [7] - Monthly cash dividends of $0.17500 per share for Series K Redeemable Preferred Stock were announced for multiple CUSIPs [8] - Monthly cash dividends of $0.17292 per share for Series K Redeemable Preferred Stock were announced for additional CUSIPs [9] - Monthly cash dividends of $0.17083 per share for Series K Redeemable Preferred Stock were announced for remaining CUSIPs [10] - Monthly cash dividends of $0.15625 per share for Series L Redeemable Preferred Stock were announced for three payment dates [11] - Monthly cash dividends of $0.16042 per share for Series M Redeemable Preferred Stock were announced for three payment dates [12][13] Company Overview - As of September 30, 2025, Ashford Hospitality Trust had 7,672,142 shares of Series J, 737,805 shares of Series K, 195,976 shares of Series L, and 433,601 shares of Series M Redeemable Preferred Stock issued and outstanding [14] - The company operates as a real estate investment trust (REIT) primarily focused on investing in upper upscale, full-service hotels [14]

Core Viewpoint - The company has received an arbitration decision allowing it to withdraw its arbitration application regarding a contract dispute, with no substantial impact on its operations or profits [1][2]. Group 1: Arbitration Case Details - The company, Guangzhou Baiyun International Airport Co., Ltd., was the applicant in an arbitration case against "China Ocean Intelligence" concerning a baggage inspection equipment contract [1]. - The arbitration decision agreed to the company's request to withdraw the arbitration application, with the case acceptance fee being zero [1]. - The company had prepaid arbitration fees of 170,035 yuan, which will be refunded, and will bear a processing fee of 25,505 yuan [1]. Group 2: Financial Impact - The arbitration decision is not expected to have a substantial impact on the company's production and operations [2]. - The company will conduct accounting treatment based on accounting standards and actual circumstances, with the impact on current or future profits to be confirmed by annual audit results [2]. Group 3: Other Legal Matters - As of the announcement date, the company and its subsidiaries do not have any other significant litigation or arbitration matters that have not been disclosed [2].

Core Viewpoint - Emergent BioSolutions Inc. has secured a contract modification to deliver Vaccinia Immune Globulin Intravenous (Human) (VIGIV) to the U.S. Department of Health and Human Services for smallpox preparedness, highlighting the company's ongoing partnership with the U.S. government [1][2]. Group 1: Contract and Partnership - The contract modification involves additional doses of VIGIV, a treatment for complications arising from smallpox vaccination, under an existing 10-year contract with the Administration for Strategic Preparedness and Response (ASPR) [1]. - This modification follows a recent contract amendment for Botulism Antitoxin Heptavalent (BAT) with ASPR, indicating a broader collaboration between Emergent and the U.S. government in public health preparedness [2]. Group 2: Product Information - VIGIV is indicated for treating complications due to vaccinia vaccination, including severe generalized vaccinia and eczema vaccinatum, but is not indicated for postvaccinial encephalitis [3][4]. - The product has specific contraindications, including isolated vaccinia keratitis and severe allergic reactions to human globulins [4]. Group 3: Safety Information - Important safety information for VIGIV includes potential interactions with glucose monitoring systems, which may lead to falsely elevated blood glucose readings [3]. - Common adverse reactions reported in clinical trials for VIGIV include headache, nausea, rigors, and dizziness, with more than 10% of patients experiencing these effects [6].